Floatz logo

Niraparib

Ovarian Carcinoma

ImunonSmall moleculePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
73/ 100

Competitive context

235 Active assets in the Ovarian Carcinoma cohort.

Asset / SponsorPhaseRating
Trabectedin
AGO Research GmbH
Phase 4BBB
Mirvetuximab Soravtansine
AstraZeneca
Phase 3BBB
Olaparib
Imunon
Phase 4BB
Carboplatin
University of Washington
Phase 3BB
Irinotecan
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

Niraparib is also rated in:

breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
ovarian neoplasmActive
BB
Indicative · Phase 4
66 / 100
View asset →
BRCA2-related cancer predispositionActive
BB
Indicative · Phase 3
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →